[{"address1": "2223 Avenida de la Playa", "address2": "Suite 208", "city": "LA Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "619 400 1170", "website": "https://www.gribio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Dr. W. Marc Hertz Ph.D.", "age": 52, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 842014, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leanne M. Kelly", "age": 46, "title": "CFO & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 550930, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.415, "open": 0.4093, "dayLow": 0.4062, "dayHigh": 0.4297, "regularMarketPreviousClose": 0.415, "regularMarketOpen": 0.4093, "regularMarketDayLow": 0.4062, "regularMarketDayHigh": 0.4297, "volume": 74030, "regularMarketVolume": 74030, "averageVolume": 328258, "averageVolume10days": 110210, "averageDailyVolume10Day": 110210, "marketCap": 1333256, "fiftyTwoWeekLow": 0.4, "fiftyTwoWeekHigh": 53.13, "fiftyDayAverage": 0.65246, "twoHundredDayAverage": 6.62319, "currency": "USD", "enterpriseValue": -460613, "floatShares": 3061948, "sharesOutstanding": 3196490, "sharesShort": 18259, "sharesShortPriorMonth": 115733, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0057, "heldPercentInsiders": 0.0418, "heldPercentInstitutions": 0.0086, "shortRatio": 0.14, "shortPercentOfFloat": 0.0057, "impliedSharesOutstanding": 3344620, "bookValue": 0.401, "priceToBook": 1.0401497, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -13037000, "trailingEps": -28.25, "lastSplitFactor": "1:7", "lastSplitDate": 1706572800, "enterpriseToEbitda": 0.041, "52WeekChange": -0.9916565, "SandP52WeekChange": 0.24486005, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GRI", "underlyingSymbol": "GRI", "shortName": "GRI Bio, Inc.", "longName": "GRI Bio, Inc.", "firstTradeDateEpochUtc": 1612967400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2a4b9e2e-4254-393c-ba83-44e16bef237a", "messageBoardId": "finmb_136941170", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.4171, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 1808000, "totalCashPerShare": 0.566, "ebitda": -11133000, "totalDebt": 14000, "quickRatio": 0.67, "currentRatio": 1.088, "debtToEquity": 5.405, "returnOnAssets": -4.16929, "freeCashflow": -5195875, "operatingCashflow": -8990000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-07"}]